Immunogenic and non-immunogenic cell death in the tumor microenvironment
JM Pitt, G Kroemer, L Zitvogel - … in cancer progression and cancer therapy, 2017 - Springer
The host immune system is continuously exposed to dying cells and has evolved to
distinguish between cell death events signaling potential threats and physiological …
distinguish between cell death events signaling potential threats and physiological …
Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune …
J Shang, X Han, H Zha, H Tao, X Li, F Yuan… - Frontiers in …, 2021 - frontiersin.org
The efficacy of current treatment regimens for pancreatic cancer (PC) remains unsatisfactory.
In recent years, immune checkpoint blockade (ICB) therapy has shown promising anti-tumor …
In recent years, immune checkpoint blockade (ICB) therapy has shown promising anti-tumor …
Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer
F Shoji, Y Morodomi, T Akamine, S Takamori… - Lung Cancer, 2016 - Elsevier
Background The most effective treatment for early-stage non-small cell lung cancer
(NSCLC) is surgical resection. Nevertheless, up to 20% of patients, even those with stage I …
(NSCLC) is surgical resection. Nevertheless, up to 20% of patients, even those with stage I …
High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer
C Perisanidis, G Kornek, PW Pöschl, D Holzinger… - Medical Oncology, 2013 - Springer
With growing evidence on the role of inflammation in carcinogenesis, the presence of a
systemic inflammatory response has been proposed as having prognostic significance in a …
systemic inflammatory response has been proposed as having prognostic significance in a …
[HTML][HTML] Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer
H Jiang, H Li, A Li, E Tang, D Xu, Y Chen, Y Zhang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
More than 50% of patients with colorectal cancer (CRC) are initially diagnosed with locally
advanced CRC (LACRC), and half of those patients develop recurrence or metastasis after …
advanced CRC (LACRC), and half of those patients develop recurrence or metastasis after …
Bioengineering solutions for manufacturing challenges in CAR T cells
The next generation of therapeutic products to be approved for the clinic is anticipated to be
cell therapies, termed “living drugs” for their capacity to dynamically and temporally respond …
cell therapies, termed “living drugs” for their capacity to dynamically and temporally respond …
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma
JS Mendez, A Govindan, J Leong, F Gao… - Journal of neuro …, 2016 - Springer
Management of patients with glioblastoma (GBM) often includes radiation (RT) and
temozolomide (TMZ). The association between severe treatment-related lymphopenia (TRL) …
temozolomide (TMZ). The association between severe treatment-related lymphopenia (TRL) …
[HTML][HTML] Prognostic significance of preoperative prognostic nutritional index in colorectal cancer: results from a retrospective cohort study and a meta-analysis
Y Yang, P Gao, X Chen, Y Song, J Shi, J Zhao, J Sun… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The preoperative prognostic nutritional index (PNI) may forecast colorectal cancer (CRC)
outcomes, but the evidence is not conclusive. Here, we retrospectively analyzed a cohort of …
outcomes, but the evidence is not conclusive. Here, we retrospectively analyzed a cohort of …
[HTML][HTML] Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment …
B Kasper, S Sleijfer, S Litière, S Marreaud, J Verweij… - Annals of oncology, 2014 - Elsevier
Background Pazopanib recently received approval for the treatment of certain soft tissue
sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two …
sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two …
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
W Xie, S Forveille, K Iribarren, A Sauvat… - …, 2019 - Taylor & Francis
Systemic treatment with the active transcription inhibitor lurbinectedin aims at inducing tumor
cell death in hyperproliferative neoplasms. Here we show that cell death induced by …
cell death in hyperproliferative neoplasms. Here we show that cell death induced by …